Novartis AG
NYSE:NVSDrug Manufacturers - General
-$3.38 today
- Market cap
- $293.13B
- Beta
- 0.49
- P/E (TTM)
- 20.7
- EPS (TTM)
- $7.06
- Dividend yield
- 3.13%
Volume 2.75M
Average 1.56M
NVS Deferred Tax Liabilities
Taxes owed in future periods because of timing differences between accounting and tax rules.
Novartis AGNYSE: NVS
Deferred Tax Liabilities · Q2 FY2026 · quarter ended Jun 2026
Deferred tax liabilities rises 128.0% from a year ago
Deferred tax liabilities stood at $5.29B at the end of Q2 FY2026, up 128.0% from a year earlier and up 3.7% from the prior quarter. Over 3 fiscal years it compounded at +44.0% a year.
Context
- Deferred tax liabilities amounted to 4.3% of total assets at the end of Q2 FY2026, up 2.1 pp from a year earlier.
- Deferred tax liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred tax liabilities keeps rising in the next quarterly balance sheet after a +128.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Tax Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 8.02B USD
- Year-over-year change
- +231.4%
- 4-year CAGR
- +27.1%
| Period | Period end | Deferred Tax Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.02B | +231.4% |
| FY2024 | 2024-12-31 | 2.42B | +7.6% |
| FY2023 | 2023-12-31 | 2.25B | -16.3% |
| FY2022 | 2022-12-31 | 2.69B | -12.5% |
| FY2021 | 2021-12-31 | 3.07B | — |
Deferred Tax Liabilities vs competitors
How NVS compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred tax liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +128.0% is the highest of 11, against a peer median of -15.1%.
- Deferred tax liabilities amounts to 4.3% of total assets for NVS, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $5.29B USD | +128.0% | +44.0% | 4.3% | |
| Sep 2026 | $4.84B USD | -19.3% | +19.4% | 2.4% | |
| Jun 2026 | DKK 4.27B DKK | -56.4% | -2.2% | 0.7% | |
| Sep 2026 | $3.61B USD | +0.2% | +6.0% | 3.0% | |
| Jun 2026 | $2.28B USD | -10.8% | -2.9% | 1.7% | |
| Jun 2026 | $1.96B USD | -20.8% | +32.9% | 1.0% | |
| Jun 2026 | €1.55B EUR | -9.4% | -3.3% | 1.2% | |
| Jun 2026 | $1.43B USD | +0.4% | -7.1% | 1.1% | |
| Jun 2026 | $333M USD | -48.9% | -46.8% | 0.7% | |
| Jun 2026 | £301.17M GBP | -42.8% | +0.2% | 0.5% | |
| Jun 2026 | $222M USD | -10.1% | -53.2% | 0.3% | |
| Peer median (excluding NVS) | — | -15.1% | -2.5% | 1.0% | |
Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12.41B | 7.52B | 13.39B | 11.46B | 11.44B |
| Short-term Investments | 15.71B | 11.1B | 569M | 1.89B | 155M |
| Net Receivables | 9.62B | 9.89B | 9.38B | 8.21B | 10.93B |
| Inventory | 6.67B | 7.18B | 5.91B | 5.72B | 6.27B |
| Other Current Assets | 216M | 315M | 466M | 1.43B | 514M |
| Total Current Assets | 45.72B | 36.91B | 30.48B | 29.7B | 30.46B |
| Property, Plant & Equipment (Net) | 13.11B | 12.2B | 10.92B | 10.87B | 12.35B |
| Goodwill | 29.6B | 29.3B | 23.34B | 24.76B | 25.57B |
| Intangible Assets | 34.18B | 31.64B | 26.88B | 26.92B | 29.41B |
| Long-term Investments | 2.27B | 1.61B | 1.83B | 1.13B | 2.3B |
| Tax Assets | 3.74B | 3.74B | 4.31B | 4.36B | 10.06B |
| Other Non-current Assets | 3.18B | 2.06B | 2.18B | 4.51B | 5.42B |
| Total Non-current Assets | 86.08B | 80.54B | 69.46B | 72.54B | 85.11B |
| Total Assets | 131.8B | 117.45B | 99.95B | 102.25B | 115.57B |
| Account Payables | 5.55B | 5.15B | 4.93B | 4.57B | 4.46B |
| Short-term Debt | 6.23B | 5.88B | 6.08B | 8.09B | 5.78B |
| Tax Payables | 3.03B | 3.37B | 2.41B | 2.23B | 2.58B |
| Deferred Revenue | 123M | 123M | 98M | 127M | 0 |
| Other Current Liabilities | 12.44B | 11.21B | 9.84B | 10.38B | 12.82B |
| Total Current Liabilities | 30.21B | 28.66B | 26.39B | 28.69B | 27.28B |
| Long-term Debt | 22.9B | 20.24B | 18.44B | 21.37B | 29.59B |
| Deferred Tax Liabilities | 3.07B | 2.69B | 2.25B | 2.42B | 8.02B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 6.17B | 4.91B | 4.52B | 4.08B | 2.48B |
| Total Non-current Liabilities | 33.77B | 29.37B | 26.81B | 29.43B | 41.74B |
| Total Liabilities | 63.97B | 58.03B | 53.2B | 58.12B | 69.02B |
| Common Stock | 901M | 890M | 825M | 793M | 766M |
| Retained Earnings | 70.99B | 63.54B | 49.65B | 46.56B | 44.72B |
| Accumulated OCI | (4.19B) | (5B) | (3.77B) | (3.26B) | 694M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 167M | 81M | 83M | 80M | 419M |
| Total Equity | 67.82B | 59.42B | 46.75B | 44.13B | 46.55B |
| Total Debt | 31.03B | 27.91B | 26.35B | 31.26B | 37.03B |
| Net Debt | 18.62B | 20.39B | 12.96B | 19.8B | 25.6B |
Novartis AG
NYSE:NVS
Intrinsic Alpha fair value
Locked
Current Price
$155.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.